Last reviewed · How we verify

NCT06309420

Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts

Completed NA Last updated 13 March 2024
What this trial tests

NA trial testing Cryogenic treatment of warts (Pixie CO2) in Warts in 54 participants. Completed in 10 August 2020.

Timeline
7 November 2019
Primary endpoint
10 August 2020
10 August 2020

Quick facts

Lead sponsorOystershell NV
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment54
Start date7 November 2019
Primary completion10 August 2020
Estimated completion10 August 2020
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Oystershell NV — full company profile →

Who can join

4 and older, any sex, with Warts. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study was set-up to evaluate clinical efficacy of Pixie CO2 versus a comparator product (Wortie®) for the treatment of common and plantar warts.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Warts

Currently open trials in the same condition.

Other Oystershell NV trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06309420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing